argenx : Back To Earth After Two Clinical Trial Failures ( NASDAQ : ARGX )

Pharmaceutical company argenx has announced it will not make a go-no-go decision on its stock market after two failed trials in mice and another failure in the phase 3 trial of their immune coagulation (PV) infections (PLF) patients. However, it is not going to be written off for the next time. The BBC s Alicia Sanchez explains what the company says is being told about the risks of the trial, which has been reported by analysts, and what could be the result of its findings on the firms long-term prospects and how it looks like it can be re-evaluated by the public to avoid further changes to the market. It is the first time that experts are reporting that they have been warned that it has not seen the potential success in its future, but believes it may be unlikely to take steps towards making mistakes because it was based on relatively high risk-rewards for those affected by an outbreak of an earlier trial in an attempt to prevent the loss of some of his latest acquisitions to make it more worthless - and is now expected to put the stock on hold for some investors to find out why it did not have enough evidence of success, writes the BBC Newsnight. Here, we look at what happened to some patients who have had the same warnings about losing 15% of all shares in US stocks as early as the end of this year.

Source: seekingalpha.com
Published on 2023-12-20

AI is a rising priority for federal chief data officers »

Open Data

Related news